Galen Partners Completes Sale of Cambrooke Therapeutics

STAMFORD, Conn., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Galen Partners, a healthcare-focused, growth equity investment firm, announced today the sale of Cambrooke Therapeutics, Inc. (“Cambrooke”) to Ajinomoto Co.

Cambrooke is a global leader and innovator in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy. Cambrooke’s product portfolio serves the needs of people with chronic health conditions reliant on Medical Foods and specialized functional foods as a central component of their daily nutritional needs. Zubeen Shroff, Managing Director of Galen Partners, remarked that “with this acquisition, Cambrooke gains access to Ajinomoto’s global nutrition and ingredient sciences expertise, and will continue leading the field of therapeutic nutrition solutions for chronic health conditions and serving its customers’ lifestyle needs, now with expanded reach and R&D capabilities”.

Cambrooke President and Chief Executive Officer Howard Lossing states that “Ajinomoto is a worldwide leader in amino acids, pharmaceuticals, high-quality seasonings, processed foods, beverages, and specialty chemicals. Ajinomoto’s corporate motto of ‘Eat Well, Live Well.’ is an elegant statement that directly reflects Cambrooke’s mission of improving lives via providing the most delicious and most nutritious Medical Foods for people with chronic health conditions.”

Galen’s investment in Cambrooke Therapeutics was the result of a proactive endeavor by the firm to identify platform investment opportunities along the food—drug continuum. Galen partnered with the company’s original founders, David and Lynn Paolella, to aid in making their vision a reality.

David Paolella stated that “From our first meeting with the Galen team, we knew we had met a group of individuals who had an appreciation for what we were all about. Galen Partners brought something far more important than investment capital to the table, they brought an industry savvy network of advisors, as well as, a strategic framework for how we might approach building a valuable enterprise.”

As the major shareholder in Cambrooke, Galen played an important role in augmenting the leadership team, guiding the commercial scale up approach, and assisting the CEO in attracting further debt and equity capital to the company. Howard Lossing, the CEO, stated that “Galen was an invaluable partner to the management team, in helping to shape a winning commercial scale up and distribution strategy that ultimately led to early interest on the part of several multi-billion dollar players looking for an ideal platform with which to enter the medical foods category.”

About Galen Partners
Founded in 1990, Galen Partners is a leading healthcare-focused growth equity investment firm. With nearly $1 billion invested over five funds, Galen has helped build more than 70 companies since our inception. The firm continues a tradition of strategic collaboration and partnership with Founders and management teams to build healthcare market leaders. Under the direction of the Managing Directors Philip Borden, David Jahns and Zubeen Shroff, Galen seeks to make investments in high-growth healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million.

For more information, please visit

About Cambrooke Therapeutics
Founded in 2000, Cambrooke a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious chronic unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy.

For more information, please visit

About Ajinomoto North America, Inc.
Ajinomoto North America, Inc. is a wholly owned subsidiary of Ajinomoto Co., Inc. Ajinomoto is recognized as a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients.

For more information, please visit

Zubeen Shroff
Office: (203) 653-6430

Source:Galen Partners